New TB vaccine candidate enters human testing
NCT ID NCT07647107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental tuberculosis vaccine called Lipovaxin in healthy adults aged 18 to 40 in Indonesia. The vaccine is given as two shots, 28 days apart, and compared to a placebo. The main goals are to check if the vaccine is safe and whether it triggers an immune response against TB.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lipovaxin tuberculosis vaccine
What this could lead to
If successful, this could pave the way for a new vaccine to prevent tuberculosis, a major global health threat.
What could go wrong
This is an early Phase 1 trial with only 60 participants, focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.
Jakarta Pusat, DKI Jakarta, 10430, Indonesia
Contact
Contact
Contact
Contact
Contact